Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

This study is comparing NABPLAGEM (a three-drug combination: nab-paclitaxel, gemcitabine, and cisplatin) versus nab-paclitaxel plus gemcitabine alone as second-line treatment for metastatic pancreatic cancer in patients with BRCA1/2 or PALB2 gene mutations. These mutations may make the cancer more sensitive to platinum-based therapy. **You may be eligible if...** - You have metastatic pancreatic cancer with a confirmed BRCA1/2 or PALB2 mutation - Your cancer progressed on FOLFIRINOX or a similar regimen as first-line treatment - You have measurable disease on imaging - You are 18 or older and have recovered from prior treatment side effects **You may NOT be eligible if...** - You have already received platinum or irinotecan-based chemotherapy for metastatic disease - You have severe organ dysfunction or active serious infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.